Evidence map›Paper›PMID 35967377›Full record

ArticleFrontiers in immunology2022

Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension.

Sébastien Sanges, Thomas Guerrier, Alain Duhamel, Lucile Guilbert, Carine Hauspie, Alexis Largy, Maïté Balden, Céline Podevin, Guillaume Lefèvre, Manel Jendoubi and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. New therapies in pulmonary arterial hypertension: Recent insights.International journal of cardiology. Congenital heart disease · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Sébastien SangesUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Thomas GuerrierUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Alain DuhamelUniv. Lille, CHU Lille, ULR2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France.
Lucile GuilbertUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Carine HauspieUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Alexis LargyUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Maïté BaldenUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Céline PodevinCHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, France.
Guillaume LefèvreUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Manel JendoubiUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Silvia SpecaUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Éric HachullaUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Vincent SobanskiUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Sylvain DubucquoiUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
David LaunayUniv. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Institute for Translational Research in InflammationCentre Hospitalier Universitaire de Lille · FRLille Inflammation Research International Center · FRUniversité Lille Nord de France · FRInserm · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Soluble markers of B cell activation are interesting diagnostic and prognostic tools in autoimmune diseases. Data in systemic sclerosis (SSc) are scarce and few studies focused on their association with disease characteristics. Methods: 1. Serum levels of 14 B cell biomarkers (β2-microglobulin, rheumatoid factor (RF), immunoglobulins (Ig) G, IgA, IgM, BAFF, APRIL, soluble (s)TACI, sBCMA sCD21, sCD23, sCD25, sCD27, CXCL13) were measured in SSc patients and healthy controls (HC). 2. Associations between these biomarkers and SSc characteristics were assessed. 3. The pathophysiological relevance of identified associations was explored by studying protein production in B cell culture supernatant. Results: In a discovery panel of 80 SSc patients encompassing the broad spectrum of disease manifestations, we observed a higher frequency of RF positivity, and increased levels of β2-microglobulin, IgG and CXCL13 compared with HC. We found significant associations between several biomarkers and SSc characteristics related to disease phenotype, activity and severity. Especially, serum IgG levels were associated with pulmonary hypertension (PH); β2-microglobulin with Nt-pro-BNP and DLCO; and BAFF with peak tricuspid regurgitation velocity (TRV). In a validation cohort of limited cutaneous SSc patients without extensive ILD, we observed lower serum IgG levels, and higher β2-microglobulin, sBCMA, sCD23 and sCD27 levels in patients with pulmonary arterial hypertension (PAH). BAFF levels strongly correlated with Nt-pro-BNP levels, FVC/DLCO ratio and peak TRV in SSc-PAH patients. Cultured SSc B cells showed increased production of various angiogenic factors (angiogenin, angiopoietin-1, VEGFR-1, PDGF-AA, MMP-8, TIMP-1, L-selectin) and decreased production of angiopoietin-2 compared to HC. Conclusion: Soluble markers of B cell activation could be relevant tools to assess organ involvements, activity and severity in SSc. Their associations with PAH could plead for a role of B cell activation in the pathogenesis of pulmonary microangiopathy. B cells may contribute to SSc vasculopathy through production of angiogenic mediators.

Indexed as

Hypertension, PulmonaryPulmonary Arterial HypertensionScleroderma, SystemicBiomarkersFamilial Primary Pulmonary HypertensionHumansImmunoglobulin GRheumatoid FactorBiomarkersImmunoglobulin GRheumatoid FactorangiogenesisBAFFB cellhumoral immunitypro-angiogenic factorspulmonary arterial hypertensionsoluble markerssystemic sclerosis

Identifiers

PMID35967377
PMCPMC9374103
OpenAlexW4288697564

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.